GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NGL Fine-Chem Ltd (NSE:NGLFINE) » Definitions » EV-to-EBIT

NGL Fine-Chem (NSE:NGLFINE) EV-to-EBIT : 14.76 (As of Jun. 01, 2025)


View and export this data going back to 2022. Start your Free Trial

What is NGL Fine-Chem EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, NGL Fine-Chem's Enterprise Value is ₹6,535 Mil. NGL Fine-Chem's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was ₹443 Mil. Therefore, NGL Fine-Chem's EV-to-EBIT for today is 14.76.

The historical rank and industry rank for NGL Fine-Chem's EV-to-EBIT or its related term are showing as below:

NSE:NGLFINE' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.43   Med: 14.04   Max: 38.05
Current: 14.76

During the past 13 years, the highest EV-to-EBIT of NGL Fine-Chem was 38.05. The lowest was 5.43. And the median was 14.04.

NSE:NGLFINE's EV-to-EBIT is ranked better than
57.99% of 688 companies
in the Drug Manufacturers industry
Industry Median: 17.055 vs NSE:NGLFINE: 14.76

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. NGL Fine-Chem's Enterprise Value for the quarter that ended in Dec. 2024 was ₹11,189 Mil. NGL Fine-Chem's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was ₹443 Mil. NGL Fine-Chem's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 3.96%.


NGL Fine-Chem EV-to-EBIT Historical Data

The historical data trend for NGL Fine-Chem's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NGL Fine-Chem EV-to-EBIT Chart

NGL Fine-Chem Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.88 11.70 17.74 25.18 22.76

NGL Fine-Chem Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.89 22.76 25.20 20.97 25.12

Competitive Comparison of NGL Fine-Chem's EV-to-EBIT

For the Drug Manufacturers - General subindustry, NGL Fine-Chem's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NGL Fine-Chem's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, NGL Fine-Chem's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where NGL Fine-Chem's EV-to-EBIT falls into.


;
;

NGL Fine-Chem EV-to-EBIT Calculation

NGL Fine-Chem's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=6535.184/442.681
=14.76

NGL Fine-Chem's current Enterprise Value is ₹6,535 Mil.
NGL Fine-Chem's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹443 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NGL Fine-Chem  (NSE:NGLFINE) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

NGL Fine-Chem's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2024 ) =EBIT / Enterprise Value (Q: Dec. 2024 )
=442.681/11189.2847
=3.96 %

NGL Fine-Chem's Enterprise Value for the quarter that ended in Dec. 2024 was ₹11,189 Mil.
NGL Fine-Chem's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹443 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NGL Fine-Chem EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of NGL Fine-Chem's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


NGL Fine-Chem Business Description

Traded in Other Exchanges
Address
301, E Square, Subhash Road, Vile Parle (East), Mumbai, MH, IND, 400057
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. The company is a manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health. Its product includes Active Pharmaceutical Ingredients (APIs) animal health, APIs human health, Intermediates and Finished dosage form, of which maximum revenue is generated from Veterinary APIs. Its geographical segments include India, Europe, Asia Pacific, United States, and Rest of the world. The Group's business activities fall within a single business segment of pharmaceuticals.

NGL Fine-Chem Headlines

No Headlines